The Prevalence and Impact of Nutritional Risk and Malnutrition in Gastrointestinal Surgical Oncology Patients: A Prospective, Observational, Multicenter, and Exploratory Study

Nutrients. 2023 Jul 24;15(14):3283. doi: 10.3390/nu15143283.

Abstract

A prospective, observational, multicenter, and exploratory study was conducted in 469 gastrointestinal cancer patients undergoing elective surgery. The Malnutrition Universal Screening Tool (MUST) and the Global Leadership Initiative on Malnutrition (GLIM) criteria were used to assess nutritional risk. On admission, 17.9% and 21.1% of patients were at moderate (MUST score 1) and severe (MUST score ≥ 2) nutritional risk, respectively. The GLIM criteria used in patients with a MUST score ≥ 2 showed moderate malnutrition in 35.3% of patients and severe in 64.6%. Forty-seven percent of patients with a MUST score ≥ 2 on admission had the same score at discharge, and 20.7% with a MUST score 0 had moderate/severe risk at discharge. Small bowel, esophageal, and gastric cancer and diabetes were predictors of malnutrition on admission. Complications were significantly higher among patients with a MUST score 1 or ≥2 either on admission (p = 0.001) or at discharge (p < 0.0001). In patients who received nutritional therapy (n = 231), 43% continued to have moderate/severe nutritional risk on discharge, and 54% of those with MUST ≥ 2 on admission maintained this score at discharge. In gastrointestinal cancer patients undergoing elective surgery, there is an urgent need for improving nutritional risk screening before and after surgery, as well as improving nutritional therapy during hospitalization.

Keywords: digestive surgery; gastrointestinal malignancies; malnutrition; oncology; prevalence.

Publication types

  • Observational Study
  • Multicenter Study

MeSH terms

  • Humans
  • Malnutrition* / diagnosis
  • Malnutrition* / epidemiology
  • Malnutrition* / etiology
  • Medical Oncology
  • Nutrition Assessment
  • Nutritional Status
  • Prevalence
  • Prospective Studies
  • Stomach Neoplasms*

Grants and funding

This research was funded by Fresenius Kabi, Barcelona, Spain.